Premium
Menopausal hormonal therapy in gynaecological cancers: An evidence‐based approach for clinical management
Author(s) -
Fenton Christine L.,
McGauran Melissa J.,
Richards Anthony M.
Publication year - 2020
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/ajo.13237
Subject(s) - medicine , gynaecological cancer , hormonal therapy , menopause , vasomotor , endometrial cancer , gynecology , hormone , cancer , adjuvant , oophorectomy , breast cancer , intensive care medicine , obstetrics , hysterectomy , oncology , surgery
Treatment for gynaecological malignancies often requires oophorectomy or loss of ovarian function from adjuvant treatment. Premature or early menopause caused by gynaecological cancer treatment may require menopausal hormonal therapy (MHT) to treat vasomotor symptoms. However, concerns exist due to theoretical risks of stimulation of hormonal‐sensitive tumours and hence increasing recurrence risk. There are small numbers of often underpowered fair to poor quality studies indicating that MHT is safe with most gynaecological malignancies. These studies are of variable quality with most being retrospective. We present the available data on this subject relative to the common types of gynaecological cancer.